Union Home and Cooperation Minister Amit Shah on 27 August 2026 said that India's response to the COVID-19 pandemic demonstrated the country's ability to rapidly scale domestic manufacturing of critical medical supplies — from PPE kits and N95 masks to home-grown vaccines. Shah made the remarks while addressing the RV Patel Pharminova Awards 2026 ceremony organised by Troikaa Pharmaceuticals Ltd at Sindhu Bhavan in Ahmedabad.

From Scarcity to Surplus: India's PPE Turnaround

Shah recalled that at the outbreak of the pandemic, domestic production of PPE kits was extremely limited and even procuring N95 masks posed a significant challenge. Within a short span, India scaled up manufacturing capacity to meet national demand and subsequently emerged as a major producer and exporter of both products. He described this transformation as emblematic of the country's industrial resolve under pressure.

"India rapidly developed indigenous capabilities across several areas during the crisis," Shah said, adding that the country's collective determination — involving the Centre, state governments, and 140 crore Indians — was central to that achievement.

Covaxin and Covishield: Vaccines in 13 Months

Shah specifically highlighted India's vaccine development timeline, noting that Covaxin and Covishield were produced within 13 months of the pandemic's onset — a feat he described as evidence of the country's scientific and industrial capacity during an unprecedented health emergency. India, he added, did not limit its efforts to self-sufficiency; it supplied vaccines to several other countries, contributing to the global fight against the disease.

"The experience showed that India could not only meet its own requirements but also assist other countries in times of crisis," Shah said.

The Role of Public Trust and Political Leadership

Shah referenced the early Janata Curfew — the voluntary public lockdown called by Prime Minister Narendra Modi — as a moment that illustrated the depth of public trust in political leadership during the crisis. He said the Prime Minister had expressed confidence that India would prevail, and that citizens had responded accordingly. "When the people of the country stand together with a resolve, any challenge can be overcome," Shah said.

R&D Self-Reliance: The Road Ahead

Linking the pandemic experience to the pharmaceutical sector's future, Shah stressed the importance of sustained investment in research and development. He said pharmaceutical organisations must contribute substantially until India builds stronger systems for R&D self-reliance. He also underlined the value of recognising researchers through industry awards, arguing that platforms such as the RV Patel Pharminova Awards play a meaningful role in encouraging innovation.

The remarks come as India's pharmaceutical industry continues to position itself as a global manufacturing hub, with the government pushing domestic R&D capability as the next frontier after production-scale success.